The good results obtained in the in vitro case validated the ability of the methodology to simulate stent-graft deployment in very tortuous arteries and led to think proper modelling of biomechanical environment could reduce the few local discrepancies found in the in vivo case.
By extending our experimental proofs to the in vitro case, we are opening up the field of criticality research to take advantage of the in vitro experimental designs.
In the Vitro case, the opposite seems to have happened.
In addition to studies of the immunomodulatory effects of MSCs in vitro, many cases of successful MSC-based immunotherapy in mammalian species in vivo have been reported for conditions such as GvHD, liver disease, chronic spinal cord injury, and other diseases.
Among the reports published to date on the use of silver-containing dressings in the treatment of infected postoperative wounds, only a few were based on randomized controlled trials conducted in appropriately large subject groups with majority being in vitro or case series studies.
Exclusion criteria were: in vitro studies, case report and review or meta-analysis.
Biomechanical reports, animal and cadaver studies, in vitro studies, case reports, literature reviews, technical notes, letters to the editor, instructional courses, studies comparing different techniques, study protocols with no results, and studies of nonsurgical interventions were excluded.
Similar results were observed in vitro in case of both angiotensin II (AngII -treated AngII -treatedrdiomyocytes.
Surprisingly, the kind of cells surviving in vitro in case of gliomas presenting EGFR amplification has not been defined in spite of years of investigation.
Records were manually reviewed and again, any animal studies, in vitro studies, case studies, general narrative reviews, and articles focusing on other entities which mentioned trabectedin were excluded.
